The red skin syndromes: Corticosteroid addiction and withdrawal

Expert Review of Dermatology

Volumn 1, Issue 4, 2006, Pages 547-561

  Rapaport, Marvin J ^a   Rapaport, Vicki ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

corticosteroids; eczema; nitric oxide; pruritus; vasoconstriction; vasodilatation

Indexed keywords

EID: 85016579409     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.4.547     Document Type: Article

References (84)

1. Rapaport MJ, Rapaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J. Am. Acad. Dermatol. 41, 435–442 (1999).
2. Engrasser PG, Hogan DJ, Stewart LA, Zug KA. Evaluation and management of the “red face”. Am. J. Contact Dermat. 10, 236–239 (1999).
3. Garner LA, Cruz PD Jr. Worsening of a recurrent facial eruption despite treatment. Am. J. Contact Dermat. 10, 81–82 (1999).
4. Katz AS, Sherertz EF. Facial dermatitis: patch test results and final diagnosis. Am. J. Contact Dermat. 10, 153–156 (1999).
5. Bender B, Prestia AE, Lynfield YL. The headlight sign in neurodermatitis. Cutis 5, 1406–1408 (1969).
6. Uehara M, Mitsuyoshi O, Sugiura H. Diagnosis and management of the red face syndrome. Dermatol. Ther. 1, 19–23 (1996).
7. Tada J, Yamasaki H, Toi Y et al. Is the face and neck pattern of atopic dermatitis in Japan a special variant? Am. J. Contact Dermat. 10, 7–11 (1999).
8. Rapaport MJ, Rapaport V. Prolonged erythema after facial laser resurfacing or phenol peel secondary to corticosteroid addiction. Dermatol. Surg. 25, 781–785 (1999).
9. Ruiz–Esparza J, Barba-Gomez JM, Gomez-De La Torre OL, David L. Erythema after laser skin resurfacing. Dermatol. Surg. 24, 31–34 (1998).
10. Nanni CA, Alster TS. Complications of cutaneous laser surgery. Dermatol. Surg. 24, 209–219 (1998).
11. Maloney BP, Millman B, Monheit G, McCollough EG. The etiology of prolonged erythema after chemical peel. Dermatol. Surg. 24, 337–341 (1998).
12. Rendon-Pellerano MI, Lentini J, Eaglstein WE, Kirsner RS, Hanft K, Pardo RJ. Laser resurfacing: usual and unusual complications. Dermatol. Surg. 25, 360–367 (1999).
13. Ratner D, Tse Y, Marchell N et al. Cutaneous laser resurfacing. J. Am. Acad. Dermatol. 41, 365–389 (1999).
14. Fisher AA. Part I. “Status cosmeticus”: a cosmetic intolerance syndrome. Cutis 46, 109–110 (1990).
15. Fisher AA. Part II. The management of eyelid dermatitis in patients with “status cosmeticus”: the cosmetic intolerance syndrome. Cutis 46, 199–201 (1990).
16. Fisher AA. Cosmetic intolerance syndrome. In: Contact Dermatitis, 4th Edition. Rietschel R, Fowler J (Eds). Williams & Wilkins PA, USA, 316–318 (1995).
17. Fisher BK. The red scrotum syndrome. Cutis 60, 139–141 (1997).
18. Rapaport M. Letters to the editor. Cutis 61, 128B (1998).
19. Fisher BK. Letters to the Editor. Cutis 61, 128B (1998).
20. Lynch PJ, Edwards L. Penile and scrotal pain. In: Genital Dermatology. Churchill Livingstone, NY, USA, 247–248 (1994).
21. English JC, Laws RA, Keough GC et al. Dermatoses of the glans penis and prepuce. J. Am. Acad. Dermatol. 37, 1–24 (1997).
22. Mroczkowski TF. Vulvodynia – a dermatovenereologist’s perspective. Int. J. Dermatol. 37, 567–569 (1998).
23. Goetsch MF. Vulvar vestibulitis: prevalence and history features in a general gynecological practice population. Am. J. Obstet. Gynecol. 164, 1609–1616 (1991).
24. Baggish MS, Miklos JR. Vulvar pain syndrome: a review. Obstet. Gynecol. Surg. 50, 618–627 (1995).
25. Lynch PJ. Vulvodynia: a syndrome of unexplained vulvar pain, psychologic disability and sexual dysfunction. The 1985 ISSVD Presidential Address. J. Reprod. Med. 31, 773 (1986).
26. McKay M. Vulvodynia. Arch. Dermatol. 125, 256–262 (1989).
27. Lewis FM, Shah M, Gawkrodger DJ. Contact sensitivity in prurutis vulvae: patch test results and clinical outcome. Am. J. Contact Dermat. 8 (3), 137–140 (1997).
28. Goldman L, Kitzmiller KW. Perianal atrophoderma from topical corticosteroids. Arch. Dermatol. 107, 611–612 (1973).
29. Lim HW, Buchness MR, Ashinoff R, Soter NA. Chronic actinic dermatitis. Arch. Dermatol. 126, 317–323 (1990).
30. Roelandts R. Chronic actinic dermatitis. J. Am. Acad. Dermatol. 28, 240–249 (1993).
31. Norris P, Hawk J. Chronic actinic dermatitis. A unifying concept. Editorials. Arch. Dermatol. 126, 376–378 (1990).
32. Lim HW, Morison WL, Kamide R et al. Chronic actinic dermatitis. Arch. Dermatol. 130, 1284–1289 (1994).
33. Lim HW, Cohen D, Soter NA. Chronic actinic dermatitis: results of patch and photopatch tests with compositae, fragrances, and pesticides. J. Am. Acad. Dermatol. 38, 108–111 (1998).
34. Menage H, Ross JS, Norris PG et al. Contact and photocontact sensitization in chronic actinic dermatitis: sesquiterpene lactone mix is an important allergen. Br. J. Dermatol. 132, 543–547 (1995).
35. Frain-Bell W, Johnson BE. Contact allergic sensitivity plants and the photosensitivity dermatitis and actinic reticuloid syndrome. Br. J. Dermatol. 101, 503–512 (1979).
36. Frain-Bell W, Scatchard M. The association of photosensitivity and atopy in the child. Br J. Dermatol. 85, 105–110 (1971).
37. Addo HA, Ferguson J, Johnson BE, Frain-Bell W. The relationship between exposure to fragrance materials and persistent light reaction in the photosensitivity dermatitis with actinic reticuloid syndrome. Br. J. Dermatol. 107, 261–274 (1982).
38. Guin JD. Eyelid dermatitis: experience in 203 cases. J. Am. Acad. Dermatol. 47, 755–765 (2002).
39. El-Samahy MH, El-Kerdani T. Value of patch testing in atopic dermatitis. Am. J. Contact Dermat. 8, 154–157 (1997).
40. Beltrani VS. The role of dust mites in atopic dermatitis. Contact Derm. 17, 431–441 (1997).
41. Eisenlohr JE. Glaucoma following the prolonged use of topical steroid medication to the eyelids. J. Am. Acad. Dermatol. 8, 878–881 (1983).
42. May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP. Cushing syndrome from percutaneous absorption of triamcinolone cream. Arch. Intern. Med. 136, 612–613 (1976).
43. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroids use associated with adrenal suppression: clinical considerations. J. Am. Acad. Dermatol. 38, 318–321 (1998).
44. Marks R, Sawyer M. Glucocorticoid-induced vasoconstriction in human skin. Arch. Dermatol. 122, 881–883 (1986).
45. Lembeck F. Mediators of vasodilatation in the skin. Br. J. Dermatol. 109, 1–9 (1983).
46. Shah VP, Peck CC, Skelly JP. ‘Vasoconstriction’ – skin blanching-assay for glucocorticoids-a critique. Arch. Dermatol. 125, 1558–1561 (1989).
47. Ganong WF. Cardiovascular regulatory mechanisms. In: Review of Medical Physiology. Holmes SA (Ed.). Appleton & Lange, CT, USA, 550–551 (1991).
48. Berne RM, Levy MN. The microcirculation and lymphatics. In: Physiology 4th Edition. Underdown E (Ed.). Mosby, MO, USA, 429–432 (1998).
49. Clayton G, Clayton F. Patty’s Industrial Hygiene and Toxicology, 3rd Edition. John Wiley & Sons 26, 4099 & 4202 (1982).
50. Ellenhorn M, Barceloux D. Medical Toxicology: Diagnosis and Treatment of Human Poisoning. Elsevier Sci. Pub. Co., 844–851 (1988).
51. Marzining M, Nussler AK, Stadler J et al. Improved methods to measure end products of nitric oxide in biological fluids. Nitric Oxide Biol. Chem. 12, 177–189 (1997).
52. Makela S, Yazdanpanah M, Adatia I, Ellis G. Disposable surgical gloves and Pasteur pipettes as potential sources of contamination in nitrate and nitrate essays. Clin. Chem. 43 (12), 2418 (1997).
53. Moshage H, Stegeman CA, Jansen PL. Determination of nitrite and nitrate in stored urine. Clin. Chem. 44 (8), 1780–1781 (1998).
54. Granger DL, Taintor RR, Boockvar KS, Hibbs JB Jr. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Greiss reaction. Methods Enzymol. 268, 142–151 (1996).
55. Sorenson GW, Odom RB. Axillary and inguinal striae induced by systemic absorption of topical corticosteroid. Cutis 17, 355–356 (1976).
56. Deffer TA, Goette DK. Distal phalangeal atrophy secondary to topical steroid therapy. Arch. Dermatol. 123, 571–572 (1987).
57. Wolf R, Tur E, Brenner S. Corticosteroid-induced disappearing digit. J. Am. Acad. Dermatol. 23, 755–756 (1990).
58. Dooms-Goossens A. Corticosteroid contact allergy: a challenge to patch testing. Am. J. Contact Dermat. 4, 120–122 (1993).
59. Jagodzinski LJ, Taylor JS, Oriba H. Allergic contact dermatitis from topical corticosteroid preparations. Am. J. Contact Dermat. 6, 67–74 (1995).
60. Schoenmakers A, Vermorken A, Degreef H, Dooms-Goossens A. Corticosteroid or steroid allergy? Contact Derm. 26, 159–162 (1992).
61. Wilkinson SM, English JSC. Hydrocortisone sensitivity: clinical features of fifty-nine cases. J. Am. Acad. Dermatol. 27, 683–687 (1992).
62. Reitamo S, Lauerma S, Stubb S et al. Delayed hypersensitivity to topical corticosteroids. J. Am. Acad. Dermatol. 14, 582–598 (1986).
63. Guin JD. Contact sensitivity to topical corticosteroids. J. Am. Acad. Dermatol. 10, 773–782 (1984).
64. Lauerma AI, Kanerva L. Contact allergy to corticosteroids. Int. J. Dermatol. 35, 92–94 (1996).
65. Murata Y, Kumano K, Ueda T et al. Systemic contact dermatitis caused by systemic corticosteroid use. Arch. Dermatol. 133, 1053–1054 (1997).
66. English JSC, Ford G, Beck MH et al. Allergic contact dermatitis from topical and systemic steroids. Contact Derm. 23, 196–198 (1990).
67. Lauerma AI, Reitamo S. Contact allergy to corticosteroids. J. Am. Acad. Dermatol. 28, 618–622 (1993).
68. Sholz JR. Corticosteroid contact allergic dermatitis-some questions. Am. J. Contact Dermat. 1, 114–142 (1990).
69. Farrel AJ, Blake DR. Nitric oxide. Ann. Rhuem. Dis. 55, 7–20 (1996).
70. Ochoa JB, Udekwu AO, Billiar TR, Cirram RD, Simmons RL, Peitzman AB. Nitric oxide levels in patients after trauma and during sepsis. Ann. Surg. 214, 621–626 (1991).
71. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43, 109–142 (1991).
72. Parks DJ, Cheung MK, Chan CC, Roberge FG. The role of nitric oxide in uveitis. Arch. Ophthalmol. 112, 544–546 (1994).
73. Everelioglu C, Turkoz Y, Hamdi ER, Inaloz S, Ozbek E, Cekman M. Increased nitric oxide production in patients with Behcet’s disease: is it a new activity marker? J. Am. Acad. Dermatol. 46, 50–54 (2002).
74. Rapaport M, Lebwohl M. Corticosteroid addiction and withdrawal in the atopic. Clin. Dermatol. 21 (3), 201–214 (2003).
75. Shaffrali CG, Colver GB, Messenger AG, Gawkrodger DJ. Experience with low dose methotrexate for the treatment of eczema in the elderly. J. Am. Acad. Dermatol. 48, 417–419 (2002).
76. Sidbury R, Hanifin JM. Old, new, and emerging therapies for atopic dermatitis. Dermatol. Clin. 18, 1–11 (2000).
77. Ellis CN, Drake LA, Pendergast MM, Abramovits W et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical steroids in adults with moderate to severe atopic dermatitis. J. Am. Acad. Dermatol. 48, 553–563 (2002).
78. Jolles S, Hughes J, Rustin M. Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. J. Am. Acad. Dermatol. 40, 121–123 (1999).
79. Berth-Jones J. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br. J. Dermatol. 147, 324–330 (2002).
80. Ljubojeviae S, Basta-Juzbasiae A, Lipozeneiae J. Steroid dermatitis resembling rosacea: aetiopathogenesis and treatment. J. Eur. Acad. Derm. Venereo. 16 (2), 121–126 (2002).
81. Topical steroid allergy and dependence. Prescrire Int. 14 (75), 21–22 (2005).
82. Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br. J. Dermatol. 152 (2), 396–399 (2005).
83. Meurer M, Fartasch M, Albrecht G et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 208 (4), 365–372 (2004).
84. Rapaport MJ, Rapaport VH. Serum nitric oxide levels in “red” patients: separating corticosteroid-addicted patients from those with chronic eczema. Arch. Dermatol. 140, 1013 (2004).